Melanocortin Receptor 4 – Drugs In Development, 2021

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 – Drugs In Development, 2021, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Melanocortin Receptor 4 (MC4R) – Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1, 3 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology, Musculoskeletal Disorders and Women's Health which include indications Obesity, Anorexia Nervosa, Cachexia, Female Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis, Rheumatoid Arthritis, Smith-Magenis Syndrome (Chromosome 17p11.2 Deletion Syndrome) and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)

– The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects

– The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Eton Pharmaceuticals Inc

LG Chem Ltd

Mallinckrodt Plc

Palatin Technologies Inc

Pfizer Inc

Rhythm Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Melanocortin Receptor 4 (MC4R) - Overview

Melanocortin Receptor 4 (MC4R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development

Eton Pharmaceuticals Inc

LG Chem Ltd

Mallinckrodt Plc

Palatin Technologies Inc

Pfizer Inc

Rhythm Pharmaceuticals Inc

Melanocortin Receptor 4 (MC4R) - Drug Profiles

bremelanotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-54640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LR-19021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-07258669 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-9610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize MC4-R for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocortin Receptor 4 (MC4R) - Dormant Products

Melanocortin Receptor 4 (MC4R) - Discontinued Products

Melanocortin Receptor 4 (MC4R) - Product Development Milestones

Featured News & Press Releases

Jul 01, 2021: Mallinckrodt announces inclusion of Acthar Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) treatment guidelines for patients with pulmonary sarcoidosis

Jun 24, 2021: PANTHERx Rare Pharmacy selected by Rhythm Pharmaceuticals to distribute IMCIVREE (setmelanotide) for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency

May 21, 2021: Rhythm Pharmaceuticals receives positive CHMP opinion for Setmelanotide for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiency

May 19, 2021: Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials

May 04, 2021: Palatin announces U.S. patent term extension for Vyleesi (bremelanotide injection)

May 03, 2021: Mallinckrodt presents data evaluating Acthar Gel (Repository Corticotropin Injection) for the treatment of severe keratitis at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting

Mar 20, 2021: Rhythm Pharmaceuticals presents new data from phase 2 basket study showing continued weight loss at up to nine months in patients with HET obesity on Setmelanotide at ENDO 2021

Mar 09, 2021: Rhythm Pharmaceuticals announces late-breaking data presentations at ENDO 2021

Jan 26, 2021: Rhythm Pharmaceuticals announces positive data with setmelanotide in additional MC4R pathway deficiency-related obesities

Jan 19, 2021: Rhythm Pharmaceuticals to provide update on phase 2 basket study and genetic sequencing efforts

Dec 22, 2020: Rhythm Pharmaceuticals announces positive topline results from pivotal Phase 3 clinical trial evaluating Setmelanotide in Bardet-Biedl and Alstrom Syndromes

Nov 27, 2020: Rhythm Pharmaceuticals announces FDA approval of IMCIVREE (setmelanotide) as first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR Deficiency

Nov 04, 2020: Rhythm Pharmaceuticals announces new clinical data on setmelanotide at ObesityWeek 2020

Oct 30, 2020: Rhythm Pharmaceuticals announces publication of results from phase 3 clinical trials of setmelanotide in The Lancet Diabetes & Endocrinology

Oct 20, 2020: City of Rockford $10 billion lawsuit against pharmaceutical giant Mallinckrodt threatened by bankruptcy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Eton Pharmaceuticals Inc, 2021

Pipeline by LG Chem Ltd, 2021

Pipeline by Mallinckrodt Plc, 2021

Pipeline by Palatin Technologies Inc, 2021

Pipeline by Pfizer Inc, 2021

Pipeline by Rhythm Pharmaceuticals Inc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports